Srpski arhiv za celokupno lekarstvo · 2016
Lymphoblastic lymphomas in children – A single-center experience from Serbia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lazić Jelena, Janić Dragana, Krstovski Nada, Rodić Predrag, Milošević Goran, Janković Srdja, Brašanac Dimitrije, Dokmanović Lidija
Аннотация
INTRODUCTION: Intensive treatment protocols used for non-Hodgkin lymphoma in children lead to eventfree survival rates ranging from 80% to 90%. However, the results are less successful in developing countries. Lymphoblastic lymphoma (LBL) is the second most frequent type of lymphoma in children, contributing with about one third to all non-Hodgkin lymphoma in childhood.
OBJECTIVE: The aim of the study was to evaluate the results of LBL treatment in University Children’s Hospital (UCH), Belgrade.
METHODS: A retrospective analysis of patient records at UCH from 1997 to 2015 was carried out in patients aged 0–18 years, in whom the diagnosis of LBL had been established. Twenty-two children were included in the analysis.
RESULTS: Mean age at diagnosis was 10 years, with preponderance of male patients. All patients were treated according to Berlin-Frankfurt-Münster-based chemotherapy protocols. With median follow-up of 91.5 months, five-year probability of event-free survival was 79.5% for all patients, while overall survival was 81.8%.
CONCLUSION: Our results, although slightly inferior to those of leading international groups, reflect a good treatment outcome in our patients.
OBJECTIVE: The aim of the study was to evaluate the results of LBL treatment in University Children’s Hospital (UCH), Belgrade.
METHODS: A retrospective analysis of patient records at UCH from 1997 to 2015 was carried out in patients aged 0–18 years, in whom the diagnosis of LBL had been established. Twenty-two children were included in the analysis.
RESULTS: Mean age at diagnosis was 10 years, with preponderance of male patients. All patients were treated according to Berlin-Frankfurt-Münster-based chemotherapy protocols. With median follow-up of 91.5 months, five-year probability of event-free survival was 79.5% for all patients, while overall survival was 81.8%.
CONCLUSION: Our results, although slightly inferior to those of leading international groups, reflect a good treatment outcome in our patients.